"An investment in knowledge pays the best interest."

TSX Penny Stocks

is a website devoted to hunting for undervalued and undiscovered TSX listed Penny Stocks.

Buying penny stocks or investing profitably in the stock market, in general, is not easy. Our penny stock investments invariably come from hard work and researching reliable sources. TSX Penny Stocks provides news and important company information so you can ultimately decide which stocks are worth your consideration.

The website offers write-ups of penny stocks and company news. Visitors can sign up to TSX Penny Stocks.ca for a free email newsletter to receive more penny stock articles, and company spotlights. Join us it’s free.

Latest News

Newsletter Sign-up

Don't Miss Another TSX Penny Stock

Subscribe

 

HEALTH CANADA GRANTS THERALASE ITA APPROVAL

Health Canada has granted Theralase Technologies Inc. (TLT.V)  investigational testing authorization (ITA) approval to use its patent-pending TLC-3200 photodynamic therapy (PDT) laser system and TLC-3400 dosimetry fibre optic cage (DFOC) technology, in conjunction with its clinical trial application-approved lead PDC, TLD-1433, to commence a phase Ib clinical trial for the treatment of non-muscle invasive bladder cancer (NMIBC).

The TLC-3200 PDT laser system delivers green laser light, at a wavelength of 525 nanometres, while the DFOC technology precisely monitors the laser light to provide a uniform distribution of the laser light energy, in the correct dosage, to the bladder wall.

Theralase, possessing both CTA and ITA approval, plans to immediately commence a phase Ib clinical study for the treatment of NMIBC.

The patient population will comprise subjects with high-risk Ta/T1 or TIS NMIBC that are intolerant or refractory to bacillus calmette-guerin (BCG) and who are not candidates or refuse radical cystectomy.

The primary objective of this study is to evaluate the safety of PDT employing TLD-1433 and controlled laser light distribution via the TLC-3200 and TLC-3400 DFOC system.

The secondary objective of this study is to evaluate the pharmacokinetics (PK) (the branch of pharmacology concerned with the movement of drugs within the body) of TLD-1433.

Roger Dumoulin-White, president and chief executive officer of Theralase, stated that: "Theralase is very proud of the hard work delivered by the team that resulted in Health Canada's decision to grant the company ITA approval of its TLC-3200 and TLC-3400 technologies. I join the entire team in stating that we look forward to commencing a phase Ib clinical study for NMIBC and demonstrating to the world what this technology is truly capable of."